A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

August 1, 2022

Study Completion Date

August 1, 2022

Conditions

Angelman Syndrome

Interventions

DRUG

RO7248824

A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.

Trial Locations (1)

Pra International Group B.V, Groningen

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY